Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Next Previous
Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; VG 2025 (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Duodenal cancer; Leiomyosarcoma; Liver cancer; Ovarian cancer; Pancreatic cancer; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Virogin Biotech

Most Recent Events

  • 08 Aug 2023 Number of treatment arms increased from 1 to 2 by the addition of Experimental: Combination Arm, where Nivolumab injection is added as a study drug.
  • 08 Aug 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
  • 06 Jun 2023 Results (n=10; as of 10 Jan 2023) reporting initial safety and efficacy data presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top